TransMedics jumps on upbeat annual revenue forecast

TransMedics

27/02/2024 11:58

** Shares of med-tech company TransMedics Group  TMDX.O 
rise 26% to ~$98 before the bell 
    ** Late Monday, co said it sees FY'24 rev to be in the range
of $360 mln to $370 mln, above analysts average estimate of
about $356 mln, as per LSEG data 
    ** The annual rev outlook represents 49% to 53% growth
compared to the company's prior year revenue 
    ** Organ transplant specialist posted a 159% increase in
total Q4 rev to $81.17 mln, also beating analysts' estimate of
$68.51 mln 
    ** Q4 net income came in at $4 mln compared to net loss of
$6.7 mln in the same period last year 
    ** Stock down 1.5% YTD, as of last close 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))